Allergan Licenses Phase I Skin Cancer Drug from Peplin
By Business Review Editor
Pharma Deals Review: Vol 2002 Issue 31 (Table of Contents)
Published: 2 Dec-2002
DOI: 10.3833/pdr.v2002.i31.966 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Allergan acquired the rights to PEP 005 product useful for treating nonmelanoma skin cancer and actinic keratosis from Peplin Biotech...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS